PHarmacological Audit study of Safety and Effectiveness in Real world (Phase R): Opioid for Cancer Dyspnea Study

PHarmacological Audit study of Safety and Effectiveness in Real world (Phase R): Opioid for Cancer Dyspnea Study - PHarmacological Audit study of Safety and Effectiveness in Real world (Phase R): Opioid for Cancer Dyspnea Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038918

Enrollment

400

Registered

2019-12-20

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer dyspnea

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adult (20 year or older) cancer patient 2) Inpatient 3) Starting regular opioid (morphine, oxycodone, hydromorphone, or fentanyl) for dyspnea

Exclusion criteria

Exclusion criteria: 1) Treatment for non-cancer etiology of dyspnea will be planed within 3 days. 2) Treatment which has potential of improving dyspnea drastically will be planed within 3 days.

Design outcomes

Primary

Measure	Time frame
Proportion of patient whose dyspnea NRS score decrease 1 point or greater 72 hours after starting regular opioid.	—

Countries

Japan

Contacts

Public ContactTakashi Yamaguchi

Kobe University Department of Palliative Medicine

ikagoro@pop06.odn.ne.jp0783826531

Outcome results